The Five Most Pivotal Psychedelics Studies So Far

March 24, 2022 14:44:25

Numerous studies on psychedelics have been conducted since the substances went mainstream a couple of years ago. Since then, a lot has been unearthed about the therapeutic benefits these drugs possess. Here are some important studies on psychedelics that are currently being conducted or are complete.

Compass Pathways phase IIb trial

Compass Pathways published data on its psychedelic clinical trial, which used psilocybin therapy to manage treatment-resistant depression in 2021. Trial results show that at least 36% of the participants saw a considerable reduction in their symptoms three weeks after the treatment has ended, with almost 30% of these participants improving enough to enter remission.

MAPS phase III trial

The Multidisciplinary Association of Psychedelic Studies (MAPS) also published data on its phase III trial in 2021. The trial evaluated the effectiveness of MDMA therapy in treating severe post-traumatic stress disorder. The study included 90 participants, some of whom were survivors of sexual assault and war veterans who had, on average, suffered from post-traumatic stress disorder for roughly 14 years.

The study’s findings show that almost 90% of the participants had seen a decrease in their symptoms.

Imperial College of London phase II trial

Researchers at the Imperial College of London, led by Dr. Robin Carhart Harris, looked into the effectiveness of psilocybin therapy in the treatment of major depressive disorder. The researchers compared the therapy’s effectiveness with that of selective serotonin reuptake inhibitors, which are the most common treatment option for this mental health condition.

The study discovered that psilocybin was just as effective in treating depression as escitalopram, which is the SSRI that researchers used for their study. In their report, the researchers note that participants who received psilocybin saw their symptoms of depression fall eight points on the 27-point scale while the symptoms of those who were treated using SSRIs reduced by only six points.

Awakn Life Sciences phase II trial

At the start of this year, Awakn released results of its phase II trial that looked into the treatment of alcohol use disorder using ketamine. While ketamine has been used as an anesthetic since the 1970s, recent studies have shown that the psychedelic can be used to treat everything from addiction to depression. The study found that more than 85% of those who received ketamine treatments remained abstinent from alcohol.

Small Pharma phase I safety trial

Last year, Small Pharma published data on its DMT clinical trial. The objective of the trial was to test the drug’s effectiveness in treating major depressive disorder. The company has progressed its DMT formulation to phase IIa clinical trials.

All those studies have helped to bring psychedelics back into the mainstream, and companies such as Delic Holdings Corp. (CSE: DELC) (OTC: DELCF) can look forward to expanding their presence across the region as more psychedelic substances get approved for different medical indications.

NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.